*Please scroll down for English news
2021年12月28日
全球领先的开放式生物制药技术平台公司药明生物（WuXi Biologics, 2269.HK）和处于临床阶段、专注于肿瘤免疫领域的韩国公司ImmuneOncia Therapeutics（以下简称ImmuneOncia）今日宣布，双方针对ImmuneOncia治疗性抗PD-L1/CD47双特异性抗体IOH-001研发和生产签署合作备忘录（MOU）。
双方管理层云签约
根据合作备忘录，ImmuneOncia公司将通过药明生物在细胞系开发、细胞培养工艺开发、生物制剂生产，以及生物测定方法开发等端到端服务推进该创新双特异性抗体研发。药明生物将支持IOH-001新药临床试验申请（IND）的所有CMC研究，助力ImmuneOncia公司加快研发进程。
ImmuneOncia公司首席执行官Heung Tae Kim先生表示：“我们很高兴与药明生物建立合作，药明生物在双抗研发和生产领域具有广泛的服务能力，能够使我们专注于实现IOH-001的治疗潜力。更重要的是，药明生物领先的技术平台将有助于确保IOH-001高效而可持续的研发进程。我们也期待在未来进一步扩大合作，为韩国患者带来更多的创新生物药。”
药明生物首席执行官陈智胜博士表示：“我们很高兴与ImmuneOncia公司建立合作，通过端到端服务和专业洞见赋能其首个双抗药物的研发和生产。目前药明生物已赋能超过60个双抗项目，在双抗CMC开发、分析方法和质量控制等领域积累了丰富的经验。我们致力于提供创新技术解决方案以及可靠稳定的生产供应链，赋能全球合作伙伴，造福广大病患。”
关于ImmuneOncia
ImmuneOncia是一家聚焦肿瘤免疫领域的生物制药公司，由Yuhan Corporation与Sorrento Therapeutics结合双方在药物开发和抗体工程方面的专业优势于2016年合资成立。公司的使命是为全球肿瘤患者带来安全和有效的创新免疫疗法，产品线包括处于II期临床研究的抗PD-L1抗体IMC-001和处于I期临床研究的抗CD47抗体IMC-002等多个免疫检查点抑制剂。2021年3月，ImmuneOncia公司将IMC-002大中华区独家权益授予思路迪医药，如需更多信息，请浏览：www.immuneoncia.com。
关于药明生物
- 滑动查看更多药明生物介绍 -
WuXi Biologics and ImmuneOncia Sign MOU for Development and Manufacturing of Anti-PD-L1/CD47 Bispecific Antibody
SHANGHAI, China, and SEOUL, South Korea
December 28, 2021
WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and ImmuneOncia Therapeutics, Inc., a clinical-stage, immuno-oncology company in South Korea, today announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnership in the development and manufacturing of IOH-001, ImmuneOncia's therapeutic bispecific antibody targeting PD-L1 and CD47.
Within the partnership, ImmuneOncia will have access to WuXi Biologics' integrated services in cell line development, cell culture development, biologics manufacturing and bioassay development. WuXi Biologics will support ImmuneOncia on the whole CMC studies of IOH-001 for Investigational New Drug (IND) application.
Heung Tae Kim, CEO of ImmuneOncia, commented, "We are excited to collaborate with WuXi Biologics. WuXi Biologics' comprehensive capabilities on bispecifics development and manufacturing will enable us to focus on realizing the therapeutic potential of IOH-001. More importantly, access to WuXi Biologics' world-leading technologies will help ensuring its efficacious and sustainable development. We look forward to expanding collaboration in the future to bring more innovative biologics for patients in South Korea."
Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are glad to partner with ImmuneOncia to proceed its first bispecific antibody into clinical development through our integrated services and know-how. At WuXi Biologics, we have demonstrated our extensive capabilities for CMC development, analytical method, and quality control by enabling over 60 bispecific projects. We are committed to providing innovative technical solutions, reliable and sustainable manufacturing supply chain for our global partners to benefit patients worldwide."
About ImmuneOncia
ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan Corporation in South Korea and Sorrento Therapeutics, Inc. in U.S. ImmuneOncia leverages both companies' expertise in drug development and antibody engineering. The company's mission is to bring safe, effective, and novel immunotherapies to oncology patients world-wide, and its diverse immune checkpoint inhibitor portfolio includes an anti-PDL1 antibody IMC-001 in Phase II, and an anti-CD47 antibody IMC-002 in Phase I. For IMC-002, ImmuneOncia signed a license agreement with 3D Medicines for the Territory of Greater China in March 2021. For more information, please visit www.immuneoncia.com.
About WuXi Biologics
- Scroll down for more company introduction -
媒体关系 PR@wuxibiologics.com
投资者关系 IR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
